市場調査レポート

商品コード

1749705

ハンチントン病治療薬の世界市場：薬剤の種類別（承認薬、適応外医薬品）・流通チャネル別（病院薬局、オンライン薬局、小売薬局）・地域別の評価、機会と予測 (2018～2032年)

Global Huntington's Disease Treatment Market Assessment, By Drug Type [Approved Drugs, Off-Label Drugs], By Distribution Channel [Hospital Pharmacies, Online Pharmacies, Retail Pharmacies], By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年06月17日
発行: Market Xcel - Markets and Data
ページ情報: 英文 225 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,800 702,480円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 6,000 878,100円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,500 1,243,975円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.35円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のハンチントン病治療薬市場は、2025～2032年の予測期間中にCAGR 12.45％を記録し、2024年の5億956万米ドルから2032年には13億278万米ドルに成長すると予測されます。同市場の成長を支えているのは、ハンチントン病の患者数の増加、医薬品や治療法に対する投資の増加、ハンチントン病に対する認識を高めるためのイニシアチブの高まり、医学研究の急速な進歩などです。UC Davis Health（カリフォルニア大学）の推計によると、ハンチントン病は世界中で約1万人に1人が罹患しています。遺伝子治療やRNA治療における最近の進歩も、市場の拡大を後押ししています。

さらに、政府や非営利団体は、患者や介護者の間で協力関係を育み、臨床試験に対する認識を高めています。こうした取り組みは、臨床試験への参加率を向上させるだけでなく、医薬品開発のタイムラインを早めています。また、進行中の臨床研究や神経変性診断薬の進歩に対する医療関係者の認識が高まっていることも、市場の成長を後押ししています。疾患修飾療法への投資の増加と、希少疾患の管理に対する政府の支援の高まりも、市場の拡大に寄与しています。

市場規模の分析と予測
- 金額ベース
市場シェアの分析と予測
- 薬剤の種類別
  - 承認薬
  - 適応外医薬品
- 流通チャネル別
  - 病院薬局
  - オンライン薬局
  - 小売薬局
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 市場シェア分析：企業別（上位5社およびその他、金額ベース、2024年）
市場マップ分析（2024年）
- 薬剤の種類別
- 流通チャネル別
- 地域別

第6章北米のハンチントン病治療薬市場の将来展望 (2018～2032年)

市場規模分析と予測
- 金額別
市場シェア分析と予測
- 薬剤の種類別
  - 承認薬
  - 適応外医薬品
- 流通チャネル別
  - 病院薬局
  - オンライン薬局
  - 小売薬局
- 国別シェア
  - 米国
  - カナダ
  - メキシコ
国別の市場評価
- 米国のハンチントン病治療薬市場の展望：将来予測（2018～2032年）*
  - 市場規模の分析と予測
  - 市場シェアの分析と予測
- カナダ
- メキシコ

すべてのセグメントは、対象となるすべての地域と国に提供されます。

第7章欧州のハンチントン病治療薬市場の将来展望 (2018～2032年)

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第8章アジア太平洋のハンチントン病治療薬市場の将来展望 (2018～2032年)

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第9章南米のハンチントン病治療薬市場の将来展望 (2018～2032年)

ブラジル
アルゼンチン

第10章中東・アフリカのハンチントン病治療薬市場の将来展望 (2018～2032年)

サウジアラビア
アラブ首長国連邦
南アフリカ

第11章需要・供給分析

第12章輸入・輸出分析

第13章バリューチェーン分析

第14章ポーターのファイブフォース分析

第15章 PESTLE分析

第16章価格分析

第17章市場力学

市場促進要因
市場の課題

第18章市場の動向と発展

第19章規制の枠組み

臨床試験
規制当局の承認

第20章特許の情勢

第21章ケーススタディ

第22章競合情勢

市場リーダー上位5社：競合マトリックス
SWOT分析：上位5社
主要企業の情勢：上位10社
- H. Lundbeck A/S
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Pfizer Inc.
- Neurocrine Biosciences, Inc.
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Prilenia Therapeutics BV

上記企業は市場シェア順ではなく、分析作業中に入手した情報に従って変更される可能性があります。

第23章戦略提言

第24章 Market Xcelについて、免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 2. Global Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 3. Global Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 4. Global Huntington's Disease Treatment Market Share (%), By Region, 2018-2032F
Figure 5. North America Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 6. North America Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 7. North America Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 8. North America Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
Figure 9. United States Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 10. United States Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 11. United States Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 12. Canada Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 13. Canada Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 14. Canada Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 15. Mexico Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 16. Mexico Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 17. Mexico Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 18. Europe Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 19. Europe Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 20. Europe Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 21. Europe Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
Figure 22. Germany Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 23. Germany Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 24. Germany Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 25. France Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 26. France Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 27. France Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 28. Italy Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 29. Italy Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 30. Italy Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 31. United Kingdom Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 32. United Kingdom Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 33. United Kingdom Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 34. Russia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 35. Russia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 36. Russia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 37. Netherlands Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 38. Netherlands Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 39. Netherlands Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 40. Spain Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 41. Spain Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 42. Spain Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 43. Turkey Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 44. Turkey Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 45. Turkey Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 46. Poland Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 47. Poland Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 48. Poland Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 49. South America Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 50. South America Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 51. South America Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 52. South America Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
Figure 53. Brazil Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 54. Brazil Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 55. Brazil Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 56. Argentina Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 57. Argentina Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 58. Argentina Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 59. Asia-Pacific Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 60. Asia-Pacific Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 61. Asia-Pacific Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 62. Asia-Pacific Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
Figure 63. India Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 64. India Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 65. India Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 66. China Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 67. China Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 68. China Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 69. Japan Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 70. Japan Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 71. Japan Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 72. Australia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 73. Australia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 74. Australia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 75. Vietnam Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 76. Vietnam Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 77. Vietnam Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 78. South Korea Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 79. South Korea Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 80. South Korea Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 81. Indonesia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 82. Indonesia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 83. Indonesia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 84. Philippines Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 85. Philippines Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 86. Philippines Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 87. Middle East & Africa Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 88. Middle East & Africa Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 89. Middle East & Africa Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 90. Middle East & Africa Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
Figure 91. Saudi Arabia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 92. Saudi Arabia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 93. Saudi Arabia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 94. UAE Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 95. UAE Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 96. UAE Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 97. South Africa Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
Figure 98. South Africa Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
Figure 99. South Africa Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
Figure 100. By Drug Type Map-Market Size (USD Million) & Growth Rate (%), 2024
Figure 101. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
Figure 102. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024

Product Code: MX13353

Global Huntington's disease treatment market is projected to witness a CAGR of 12.45% during the forecast period 2025-2032, growing from USD 509.56 million in 2024 to USD 1302.78 million in 2032. The market's growth is supported by the rising cases of Huntington's disease, increasing investments towards pharmaceutical products and therapies, rising initiatives to increase awareness about the condition, and rapid advancements in medical research. As per the estimates of UC Davis Health (University of California), Huntington's disease affects about 1 in 10,000 people across the globe. Recent advancements in gene therapies and RNA therapeutics are also supporting the market's expansion.

Additionally, government and nonprofit organizations are fostering collaborations and clinical trial awareness among patients and caregivers. These efforts are not only improving trial participation rates but also accelerating drug development timelines. The market's growth is also driven by the increasing awareness among medical professionals about the ongoing clinical research and advancements in neurodegenerative diagnostics. Increasing investments in disease-modifying therapies coupled with the rising government support for the management of rare diseases is also contributing towards the market's expansion.

Advancements in Early Disease Detection and Treatment Support Market Growth

Early diagnosis and intervention are essential for the management of neurodegenerative disorders such as Huntington's disease. Modern testing techniques aid in the identification of individuals carrying Huntington's disease gene mutation, even before the occurrence of symptoms. This early identification for genetic counseling, clinical monitoring, and enrollment in clinical trials in a time-efficient manner. This in turn is allowing pharmaceutical companies to develop novel drugs, that are able to halt or slow the progression of the disease, providing lucrative growth opportunities for the market. For instance, in February 2025, Latus Bio, Inc. released data in support of its preclinical gene therapy program for Huntington's disease. The company introduced a new computational model for predicting the effects of the knockdown of MSH3 on reducing somatic instability. The company aims to use its AAV-DB-3 capsid variant for delivering an engineered mRNA to reduce the MSH3 in the cells that are affected by Huntington's disease.

Regulatory Approvals Support Market Expansion

Increasing regulatory support and approvals are propelling the market's expansion as they accelerate the adoption and accessibility of new therapeutic solutions. Regulatory bodies such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) are granting regenerative medicine advanced therapy and breakthrough therapy to promising candidates to ensure the availability of advanced therapies and incentivize the leading pharmaceutical companies to invest in Huntington's disease treatments. The provision of such designations facilitates faster drug development and review, ensuring the entry of innovative treatments. For instance, in April 2025, the US FDA granted breakthrough therapy designation to AMT-130 for treating Huntington's disease. Unlike current therapies available in the market, AMT-130 aims to address the underlying genetic cause of the condition and provide long-term solutions for Huntington's. As new drugs and gene therapies progress through clinical stages, the market is expected to expand rapidly, due to improved clinical outcomes and patient access.

Hospital Pharmacies Hold Significant Share of the Market

The segment's dominance is supported by the central role played by hospital pharmacies in the management of complex diseases such as Huntington's disease. A large portion of Huntington's disease medications, including deutetrabenazine and tetrabenazine, often necessitate close medical supervision and are prescription-only. Hospital pharmacies are well-equipped to ensure that both outpatients and inpatients have access to the necessary drugs and are often under the care of multidisciplinary teams such as genetic counselors, neurologists, and psychiatrists. Moreover, hospital pharmacies offer comprehensive services including medication monitoring, management of side effects, and adjustments to treatment regimens, which are crucial for Huntington's disease patients who may experience rapid changes in symptoms.

Meanwhile, leading hospital pharmacies are focusing on expanding their market presence, contributing to the segment's expansion. For instance, in March 2025, Apollo HealthCo Ltd, operator of the online platform Apollo 24/7 and Apollo Pharmacy, announced the expansion of its offline hospital pharmacy network in Bengal, India.

North America Holds a Major Market Share

The region's dominance can be attributed to the strong presence of leading pharmaceutical companies, high investments in research activities, and increasing cases of Huntington's disease in countries such as the United States and Canada. As per the estimates of the Huntington's Disease Society of America, approximately 41,000 Americans have Huntington's, and 200,000 Americans are at risk of inheriting the disease.

The market also benefits from favorable reimbursement policies and high levels of awareness among clinicians and the general population. The US FDA's stance on gene therapies and orphan drugs incentivizes companies to pursue treatments for Huntington's disease. Furthermore, organizations such as Huntington's Disease Society of America and the Hereditary Disease Foundation play a key role in advocacy, funding, and education. Canada, too, is witnessing a rise in Huntington's disease research with several centers of excellence and registry programs promoting real-world data collection. The region also benefits from numerous clinical trials and significant investments in neurodegenerative diseases.

Impact of the U.S. Tariffs on Global Huntington's Disease Treatment Market

The financial strain from the tariffs may divert resources away from research and development activities, forcing companies to scale back on or postpone clinical trials for Huntington's disease therapies due to rising operational costs. This could result in delays in the availability of novel therapeutic solutions and could slow the progress of promising treatments, including gene therapies, which are currently under various stages of development. In response to the tariffs, leading pharmaceutical companies are considering reshoring their manufacturing sites to the United States and diversifying their supply chains. The uncertainties surrounding the trade policies are also deterring investments in Huntington's research, impacting the market's expansion.

Key Players Landscape and Outlook

The key players in the market are actively focusing on developing novel therapeutic solutions that target the root cause of the disease and its progression and provide symptomatic relief. Additionally, the companies are also engaging in mergers and acquisitions to enhance their neurodegenerative pipeline. For instance, in December 2024, H. Lundbeck A/S completed the acquisition of Longboard Pharmaceuticals, Inc., allowing the company to expand its Huntington's portfolio. With Lundbeck's established expertise in neurology and global reach, Longboard's neflamapimod can be efficiently developed, commercialized, and made accessible to a broader patient base. Such acquisitions are expected to support the leading players in the market in expanding their customer base and strengthening their position in the market.

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Huntington's Disease Treatment Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Drug Type
  - 5.2.1.1. Approved Drugs
    - 5.2.1.1.1. Tetrabenazine
    - 5.2.1.1.2. Deutetrabenazine
    - 5.2.1.1.3. Valbenazine
  - 5.2.1.2. Off-Label Drugs
    - 5.2.1.2.1. Antipsychotics
    - 5.2.1.2.2. Antidepressants
- 5.2.2. By Distribution Channel
  - 5.2.2.1. Hospital Pharmacies
  - 5.2.2.2. Online Pharmacies
  - 5.2.2.3. Retail Pharmacies
- 5.2.3. By Region
  - 5.2.3.1. North America
  - 5.2.3.2. Europe
  - 5.2.3.3. Asia-Pacific
  - 5.2.3.4. South America
  - 5.2.3.5. Middle East and Africa
- 5.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
- 5.3.1. By Drug Type
- 5.3.2. By Distribution Channel
- 5.3.3. By Region

6. North America Huntington's Disease Treatment Market Outlook, 2018-2032F

6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
6.2. Market Share Analysis & Forecast
- 6.2.1. By Drug Type
  - 6.2.1.1. Approved Drugs
    - 6.2.1.1.1. Tetrabenazine
    - 6.2.1.1.2. Deutetrabenazine
    - 6.2.1.1.3. Valbenazine
  - 6.2.1.2. Off-Label Drugs
    - 6.2.1.2.1. Antipsychotics
    - 6.2.1.2.2. Antidepressants
- 6.2.2. By Distribution Channel
  - 6.2.2.1. Hospital Pharmacies
  - 6.2.2.2. Online Pharmacies
  - 6.2.2.3. Retail Pharmacies
- 6.2.3. By Country Share
  - 6.2.3.1. United States
  - 6.2.3.2. Canada
  - 6.2.3.3. Mexico
6.3. Country Market Assessment
- 6.3.1. United States Huntington's Disease Treatment Market Outlook, 2018-2032F*
  - 6.3.1.1. Market Size Analysis & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share Analysis & Forecast
    - 6.3.1.2.1. By Drug Type
      - 6.3.1.2.1.1. Approved Drugs
      - 6.3.1.2.1.1.1. Tetrabenazine
      - 6.3.1.2.1.1.2. Deutetrabenazine
      - 6.3.1.2.1.1.3. Valbenazine
      - 6.3.1.2.1.2. Off-Label Drugs
      - 6.3.1.2.1.2.1. Antipsychotics
      - 6.3.1.2.1.2.2. Antidepressants
    - 6.3.1.2.2. By Distribution Channel
      - 6.3.1.2.2.1. Hospital Pharmacies
      - 6.3.1.2.2.2. Online Pharmacies
      - 6.3.1.2.2.3. Retail Pharmacies
- 6.3.2. Canada
- 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Huntington's Disease Treatment Market Outlook, 2018-2032F

7.1. Germany
7.2. France
7.3. Italy
7.4. United Kingdom
7.5. Russia
7.6. Netherlands
7.7. Spain
7.8. Turkey
7.9. Poland

8. Asia-Pacific Huntington's Disease Treatment Market Outlook, 2018-2032F

8.1. India
8.2. China
8.3. Japan
8.4. Australia
8.5. Vietnam
8.6. South Korea
8.7. Indonesia
8.8. Philippines

9. South America Huntington's Disease Treatment Market Outlook, 2018-2032F

9.1. Brazil
9.2. Argentina

10. Middle East and Africa Huntington's Disease Treatment Market Outlook, 2018-2032F

10.1. Saudi Arabia
10.2. UAE
10.3. South Africa

11. Demand Supply Analysis

12. Import and Export Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

17.1. Market Drivers
17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

19.1. Clinical Trials
19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

22.1. Competition Matrix of Top 5 Market Leaders
22.2. SWOT Analysis for Top 5 Players
22.3. Key Players Landscape for Top 10 Market Players
- 22.3.1. H. Lundbeck A/S
  - 22.3.1.1. Company Details
  - 22.3.1.2. Key Management Personnel
  - 22.3.1.3. Products and Services
  - 22.3.1.4. Financials (As Reported)
  - 22.3.1.5. Key Market Focus and Geographical Presence
  - 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 22.3.2. Bausch Health Companies Inc.
- 22.3.3. Sun Pharmaceutical Industries Ltd.
- 22.3.4. Teva Pharmaceuticals Industries Ltd.
- 22.3.5. Dr. Reddy's Laboratories Ltd.
- 22.3.6. Pfizer Inc.
- 22.3.7. Neurocrine Biosciences, Inc.
- 22.3.8. Hikma Pharmaceuticals PLC
- 22.3.9. Lupin Limited
- 22.3.10. Prilenia Therapeutics B.V.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

ハンチントン病治療薬の世界市場：薬剤の種類別（承認薬、適応外医薬品）・流通チャネル別（病院薬局、オンライン薬局、小売薬局）・地域別の評価、機会と予測 (2018～2032年)

Global Huntington's Disease Treatment Market Assessment, By Drug Type [Approved Drugs, Off-Label Drugs], By Distribution Channel [Hospital Pharmacies, Online Pharmacies, Retail Pharmacies], By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 分析手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界のハンチントン病治療薬市場の将来展望 (2018～2032年)

第6章 北米のハンチントン病治療薬市場の将来展望 (2018～2032年)

第7章 欧州のハンチントン病治療薬市場の将来展望 (2018～2032年)

第8章 アジア太平洋のハンチントン病治療薬市場の将来展望 (2018～2032年)

第9章 南米のハンチントン病治療薬市場の将来展望 (2018～2032年)

第10章 中東・アフリカのハンチントン病治療薬市場の将来展望 (2018～2032年)

第11章 需要・供給分析

第12章 輸入・輸出分析

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析